English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Alzheimer's disease (AD) is the most common form of dementia, characterized by progressive loss of memory and cognitive dysfunctions. A central pathological event of AD is accumulation and deposition of cytotoxic amyloid- β  peptide (A β ) in the brain parenchyma. Heparan sulfate proteoglycans (HSPGs) and the side chains heparan sulfate (HS) are found associated with A β  deposits in the brains of AD patients and transgenic animal models of AD. A growing body of evidence from  in vitro  and  in vivo  studies suggests functional roles of HSPG/HS in A β  pathogenesis. Although the question of “how and why HSPG/HS is codeposited with A β ?” still remains, it is within reach to understand the mechanisms of the events. Recent progress by immunohistochemical examination with advanced antibodies shed light on molecular structures of HS codeposited with A β . Several recent reports have provided important new insights into the roles of HSPG in A β  pathogenesis. Particularly, experiments on mouse models revealed indispensible functions of HSPG in modulating A β -associated neuroinflammation and clearance of A β  from the brain. Application of molecules to interfere with the interaction between HS and A β  peptides has demonstrated beneficial effects on AD mouse models. Elucidating the functions of HSPG/HS in A β  deposition and toxicity is leading to further understanding of the complex pathology of AD. The progress is encouraging development of new treatments for AD by targeting HS-A β  interactions.

Towards Understanding the Roles of Heparan Sulfate Proteoglycans in Alzheimer’s Disease